The Covid-19 pandemic has introduced an array of organ-specific and systemic phenotypes- some previously observed in viral infections, including severe acute respiratory syndrome (SARS) and others that appear to be unique to SARS-coronavirus (CoV)-2. Rapidly emerging information from clinical observations, autopsy-based findings, extrapolations from in vitro and ex vivo studies and dynamic modeling are informing management guidelines; however, many questions remain unanswered and clinical trials that are required to provide evidence have not been completed in most areas. Among the many questions that require careful thought, reflection and investigation are the mechanism(s) underlying the development of a systemic coagulopathy and acquired thrombophilia characterized in a majority of cases by a proclivity for venous, arterial and microvascular thrombosis.

The following review summarizes emerging insights into the pathobiology, mechanism(s), diagnosis, management, foundations for research and either planned or ongoing clinical trials for Covid-19-associated coagulopathy.

Venous and arterial thrombosis in Covid-19 infection

Klok et al. [1] evaluated the occurrence of venous and arterial thrombotic events, including deep vein thrombosis (DVT), pulmonary embolism (PE), ischemic stroke, myocardial infarction and systemic arterial events in 184 patients with Covid-19 pneumonia admitted to the intensive care unit (ICU). All patients received standard thromboprophylaxis (Nadroparin 2850 to 5700 IU per day based on body weight). The composite incidence of thrombotic events was 31%. Venous thromboembolic events were the most common (27%) and a majority were PEs. Independent predictors of thrombotic events were increased age and evidence on screening blood tests for a coagulopathy (prothrombin time [PT] > 3 s above the upper limit of normal [ULN]), activated partial thromboplastin time [APTT] > 5 s above the ULN; adjusted hazard ratio 4.1, 95% CI 1.9–9.1). None of the patients experiencing thrombotic events met strict criteria for disseminated intravascular coagulation (DIC).

Tang et al. reported on abnormal coagulation parameters and poor prognosis in 183 consecutive patients with Covid-19 pneumonia [2]. Those who did not survive their illness compared with survivors had higher D-dimer levels, fibrin(ogen) degradation products (FDP) and longer PT and APTT values. Abnormal coagulation parameters were evident early after hospitalization and in some patients, fibrinogen concentrations and antithrombin activity decreased over time.

The same investigators [3] reported in 445 patients that anticoagulant therapy, primarily with low molecular weight heparin (LMWH) administered for 7 days or longer was associated with a lower 28-day morality when administered to patients with a sepsis-induced coagulopathy (SIC) score ≥ 4 or a D-dimer value greater than 6 times the ULN. The SIC score is derived from the platelet count, PT ratio, FDPs, systemic inflammatory response syndrome (SIRS) score and a sequential organ system failure assessment.

Helms et al. [4] reported the occurrence of thrombotic events among 150 patients with Covid-19 and acute respiratory distress syndrome (ARDS) admitted to the ICU. Propensity matching was undertaken to determine the risk of thromboembolic events for patients with Covid-19 and those with non-Covid-19 infection-associated ARDS. Twenty-five patients (16.7%) experienced a PE; among 29 patients undergoing renal replacement therapy 28 (96.6%) experienced circuit clotting and of 12 patients requiring extracorporeal membrane oxygenation (ECMO) for refractory hypoxemia, three thrombotic circuit occlusions (in two patients) occurred. Lupus anticoagulants were detected in 50 of 57 patients tested (87.7%). In patients with non-Covid-19 infection-associated ARDS, 2.1% experienced a PE. The investigators also reported that patients with Covid-19-associated ARDS did not develop DIC and had markedly elevated circulating levels of Von Willebrand factor (VWF) antigen, VWF activity and factor VIII [5].

Perhaps one of the least expected and most striking complications of Covid-19 is acute large vessel occlusion with ischemic stroke in patients less than 50 years of age [6]. Among the 5 patients reported by Oxley et al., the youngest was 33 years of age and the mean NIHSS score was 17, consistent with severe large vessel stroke. In the original cases reported from Wuhan China, stroke was seen in 5% of patients [31] and liberation of “platelet microbial” proteins and peptides, including platelet factor (PF)-4, regulated on activation, normal T cell expressed and secreted (RANTES), and fibrinopeptide B. Platelets may also play an important role in the clearance of viral pathogens. Platelet interactions with leukocytes trigger recruitment and tissue infiltration necessary for pathogen clearance (reviewed in Guo [32]. In critically ill patients, thrombocytopenia correlates with multi-organ failure and death, and a decline in platelet count, even in the absence of overt thrombocytopenia, portends a worse outcome [33]. As mentioned previously, a unique feature of Covid-19 infection is the presence of extramedullary megakaryocytes that actively produce platelets.

NETs as a unifying theme in Covid-19 infection and thrombosis phenotypes

In response to strong stimulation, neutrophils, and to a lesser degree monocytes and eosinophils, release extracellular traps (ETs), consisting of DNA and histones (Fig. 3) in a process known as NETosis. The process involves histone (H) citrullination (Cit) by peptidylarginine deiminase (PAD)-4, chromatin unwinding, breakdown of nuclear membranes and cytolysis [34, 35]. There is also a vital or “non-lytic” NETosis, wherein nuclear materials (eg. DNA and histones) are released without cellular membrane disruption [36, 37].

Fig. 3
figure 3

Neutrophil extracellular traps (NETs) consist of extracellular chromatin strands (nucleic acids, DNA) wrapped around histones (nucleosomes) and inter-woven with fibrin strands. NETs are an ideal foundation or template for binding activated platelets, erythrocytes and leukocytes, activating factor XI and generating thrombin for fibrin production

Full size image

Circulating cell-free (cf) nucleic acids are DNA and RNA species present in either serum or plasma. Circulating cf-DNA in healthy individuals originates primarily from apoptotic cells and is truncated to small and uniform DNA fragments of 188–200 base pairs. By contrast, cf-DNA released in the setting of infection is the result of cellular and tissue necrosis, apoptosis, autophagy or mitotic catastrophe [38] (Fig. 4).

Fig. 4
figure 4

D-dimer is a fibrin degradation product or small protein fragment present in the peripheral blood after fibrin is formed from fibrinogen (in the presence of thrombin) and subsequently degraded by plasminogen activators. Its name is derived from having D fragments of the fibrin protein joined by a covalently bound cross-link (factor XIII)

Full size image

SARS-CoV-2 is an RNA virus. This may be pathologically and clinically relevant for several reasons. Nakazawa et al. first identified cf-RNA that could initiate coagulation by serving as a cofactor for the auto-activation of factor VII-activating protease [39]. Kannemeier et al. performed a series of experiments to determine the functional significance of intracellular material exposed to blood following tissue injury. Extracellular RNA was found to activate proteases of the contact system of coagulation, including factors XI and XII—both of which exhibited strong RNA binding. Administration of RNA provoked a thrombotic response and RNA exposed following vascular injury with ferric chloride (FeCl3) was less prothrombotic in mice pre-treated with RNAase. Thus, under conditions characterized by tissue injury, extracellular RNA serves as a template for contact activation–dependent thrombosis [40].

Gajsiewicz et al. [41] investigated the ability of polyphosphates to modulate the contact-mediated pathway of coagulation. They observed that polyphosphates facilitated factor XI activation. Secondary structures of RNA, particularly hair-pin forming oligomers are highly procoagulant. There is an RNA length-contact activation relationship (reviewed in Baker [42], however, even relatively short polyphosphates released from activated platelets accelerate factor V activation, inhibit the anticoagulant activity of tissue factor pathway inhibitor (TFPI), promote factor XI activation by thrombin, and contribute to the synthesis of thicker fibrin strands that are resistant in fibrinolysis. Extracellular polyphosphates and nucleic acids (RNA and DNA) often co-localize following cellular injury and in highly inflammatory environments.

Tissue NETs cause platelet activation and thrombosis, possibly from NET-associated histones that can induce platelet aggregation through toll-like receptors (TLRs) on platelets and other cells. Platelet signaling activates the major platelet adhesion receptor, integrin αIIbβ3, which mediates platelet aggregation, as well granule release, phosphatidylserine exposure, FV/Va expression and thrombin generation [43,44,45]. NETs are recognized as linking inflammation, coagulation and thrombosis both locally and systemically in multiple conditions [46].

Zuo et al. [47] reported high levels of circulating cf-DNA and DNA-myeloperoxidase complexes in patients with Covid-19. The levels correlated with the acuity of illness, inflammatory response and need for mechanical ventilation.

More on the platelet-NET interface

Platelets play a pivotal role in the recruitment of neutrophils to sites of inflammation as well as their subsequent trans-endothelial migration. Von Willebrand Factor (VWF) is actively involved in this process. The interaction of platelets and neutrophils, to include NET formation, occurs through several signaling pathways independent of platelet aggregation and thrombosis (reviewed in Pitchford) [48]. Accumulation of platelets and VWF within microvessels is a unifying step for endothelial cell activation, impaired vascular integrity, leukocyte recruitment, trans-endothelial migration, tissue inflammation, and target organ injury [49].

While platelets dissociate from leukocytes during trans-endothelial migration in high shear stress conditions, platelet-leukocyte complexes can remain intact under low mechanical stress as well [50]. Inflammation and its triggers stimulate the formation of ultra-large VWF fibers that become immobilized on the endothelial cell surface where they are transformed to highly adhesive strings under shear conditions [51].

Platelets contain functional RNA that can be transferred to other cells in a process referred to as horizontal transfer (reviewed in Clancy) [52]. The transfer of platelet cytosolic RNA to nucleated cells increases protein translation and biological effects at the vascular level and, if the recipient cell undergoes trans-endothelial migration, at the tissue level [53]. Platelet micro-vesicles are also an important source of RNA that can be transferred to a variety of cells, including neutrophils, T lymphocytes, monocytes, macrophages and smooth muscle cells (reviewed in Edelstein) [54].

NETs and microvascular thrombosis

NETs represent part of a continuum of sterile inflammation and thrombosis that can involve all vascular beds, including the microvascular circulation [55,56,57,58,59,60,61,62,63,64,65,66].

The contribution of Von Willebrand factor

While NETs “trap” bacteria and other pathogens [67], they can also injure host tissues through the release of proteolytic proteins [68]. Similar processes have been described in the heart. For example, ischemia–reperfusion injury of the myocardium causes an increase in plasma nucleosomes, but in addition, there is abundant neutrophil infiltration at the tissue level and citrullinated histone H3 at the site of injury. [69, 70].

Von Willebrand Factor Kinetics in Covid-19 infection

Escher et al. identified several unique features in a patient with Covid-19 pneumonia and ARDS [71]. In addition to a continued rise in D-dimer levels, as others have reported, the patient had anti-cardiolipin antibodies (IgM) and IgM anti-β2-GPI, a marked increase in VWF antigen, VWF activity (~ fourfold above the ULN) and factor VIII levels. The findings are consistent with wide-scale systemic vascular endothelial cell activation.

Covid-19-associated coagulopathy: are the lungs a potential site of origin?

Covid-19 begins in a majority of symptomatic persons as an upper respiratory tract illness with rhinorrhea, anosmia, cough and fever. In those in whom clinical progression takes place, there is involvement of the lower respiratory tract. The typical features that in parallel include chest CT findings of bilateral patchy infiltrates and a “ground glass” pattern, coupled with biopsy and autopsy findings raise an important question about the lungs as a primary source of Covid-19- associated coagulopathy.

Consider the following well recognized properties and characteristics of the lungs under normal and pathological conditions (reviewed in Moldoveanu [72]. First, being a primary portal for entry of pathogens the lungs have robust innate (non-specific) and adaptive (specific) immunity potential and reserve. Epithelial cells secrete mucins, defensins, lactoferrin and nitric oxide as an early defense. They also secrete IL-1β, tumor necrosis factor (TNF)-α, granulocyte–macrophage colony stimulating factor (GM-CSF) and platelet activating factor to recruit inflammatory cells. Second, dendritic cells and macrophages line the respiratory tree where they present and phagocytose pathogens and also secrete chemokines, cytokines and other inflammatory mediators. Third, lymphocytes are present throughout the airways and lung parenchyma. T cells provide cell-mediated immunity and β-cells are responsible for human immune responses by synthesizing antibodies. Forth, neutrophils are recruited rapidly to sites of infection or injury where they migrate from capillaries into alveolar and interstitial spaces. NETs, as previously described have platelet and contact protease activating potential, complex with histones that have cytotoxic effects and, in addition, produce DNA-myeloperoxidase complexes that can enter the circulation and exert proinflammatory and prothrombotic effects “at a distance” from the initial cluster [46]. Viral infections typically activate the innate immune system through toll-like receptors (TLRs) that recognize molecular patterns (pathogen-associated molecular patterns or PAMPs) [73]. T helper cells produce IF-γ.

Among the most important functional roll held by the lungs during infection is regulation of inflammatory responses and maintenance of systemic homeostasis. Continued activation of TLRs exerts a negative feedback loop through ILs and TGF- β that down-regulates proinflammatory cytokine production and resulting inflammatory responses [74]. In addition, neural-immune interactions may contribute to suppressing inflammatory signals [75]. A failure to down-regulate or control the needed intensity of inflammation is a common observation in fatal Covid-19 infection.

Among the most consistent, yet unexpected findings at autopsy among decedents of COVID-19 is extramedullary megakaryocytes within the microvessels serving most major organs, including the lungs. Might there be a connection to Covid-19 pneumonia? Is there a possible connection to Covid-19-associated coagulopathy?

Megakaryocytes circulate through the pulmonary microcirculation and release platelets in a dynamic fashion [76]. The bone marrow is the site of origin for pulmonary megakaryocites and, while anchored within the pulmonary vascular can contribute substantially to platelet biogenesis. Pulmonary megakaryocytes and haematopoietic progenitor cells can migrate to and repopulate bone marrow stores.

The density of pulmonary megakaryocytes increases with infection, impaired lung function, cardiovascular disease and circulatory compromise [77]. Increased pulmonary thrombopoies is observed in patients with acute lung injury and ARDS (reviewed in Weyrich) [78] and activated platelets themselves can contribute to further injury. The number of circulating megakaryocytes is determined by pulmonary and systemic conditions. The available evidence suggests that ~ 90% of intact megakaryocytes of pulmonary origin remain in the microcirculation of the lungs; however, an increased proportion can leave and enter the arterial circulation in the presence of lung infection and inflammation [79]. Platelet production from megakaryocytes in the peripheral circulation can occur.

The high density of entrapped neutrophils in the lungs of Covid-19 decedents described by Fox et al. [9] could represent a proinflammatory and prothrombotic manufacturing plant that produces in a poorly regulated state the conditions necessary and sufficient for Covid-19-associated coagulopathy.

The profound cytokine response observed in critically ill patients with Covid-19 and similarities with secondary HLH or macrophage activation syndrome raise the possibility that drugs designed to inhibit one or more pathogenic cytokines in the lungs may have both local and systemic benefit. Several targets for treatment include IL1β (canakinumab), IL6 (tocilizumab), (TNF)-α (infliximab) and (GM-CSF) (lanzilumab) to name a few. While Covid-19 infection involves multiple organs, the initial infection in a majority of cases is pulmonary in origin. Accordingly, therapies that target early lung infections with the goal to minimize accelerating or escalating disease acuity, excessive immune response, hyper-inflammation, cytokine storm syndrome and systemic pathological effects may have a favorable effect on the initiation and steady progression of Covid-19-associated coagulopathy. This hypothesis will require testing-ideally, in the form of prospectively designed substudies of ongoing clinical trials targeting SARS-CoV-2 and its associated cytotoxic and heightened inflammatory properties.

Distinguishing laboratory features of Covid-19-associated Coagulopathy

A consistent observation among patients with Covid-19, particularly those with severe illness is an elevation of D-dimer in the peripheral blood (reviewed in Becker) [80]. The large case series of patients with COVID-19 (n = 5700) in the New York City area included baseline measures of D-dimer [81]. The median level was 438 ng/ml (IQR: 262–872 ng/ml) (Reference normal range [0–229 ng/ml]).

D-dimer is a degradation product of fibrin, formed as a result of the conversion of fibrinogen to fibrin employing thrombin as a catalyst. The presence of D-dimer in the circulation signals the breakdown of fibrin polymers by plasmin. The terminology of D-dimer is based on its containment of two D-fragments of fibrin joined by a cross-link (factor XIII). While the presence of D-dimer within the peripheral circulation supports existing thrombus and correlates directly with the burden of fibrin that subsequently undergoes lysis, it does not specify the site(s) of thrombus.

The well-characterized pathogenesis and diagnosis of disseminated intravascular coagulation (DIC) are relevant for a discussion of Covid-19-associated coagulopathy [82]. DIC is recognized for its contribution to multi-organ system failure caused by platelet–fibrin thrombi in the microvasculature and concomitant bleeding phenotype caused by consumption of coagulation factors and thrombocytopenia. A common underlying theme that is believed to be responsible for DIC is systemic inflammation, the presence of and exposure of circulating coagulation proteins to tissue factor and diffuse vascular endothelial cell injury/dysfunction with critical loss of physiologic anticoagulants and fibrinolytic proteins, including tissue plasminogen activator and urokinase-like plasminogen activator.

Fibrin(ogen) degradation products, including D-dimer cause platelet activation [83, 84]. There is a direct correlation between the mass of FDPs and the degree of platelet activation. Platelet glycoprotein VI, in its dimeric form, binds to both collagen (in the early stage of thrombosis), fibrin D fragment and D-dimer facilitating platelet aggregation at sites of fibrin formation [85]. In fact, platelet GPVI may serve as receptor for polymerized fibrin that amplifies thrombin generation and recruits additional circulating platelets to the site of thrombus development.

The unique nature of Covid-19-associated coagulopathy and thrombophilia was underscored in a small case series by Panigada et al. [86]. A total of 24 laboratory-confirmed patients was included. Employing whole blood thromboelastography (TEG) features of heightened coagulation parameters were identified (decreased R [time to fibrin formation] and K [time to 20 mm clot] values and increased K angle [speed to clot, 20 mm] and MA [clot strength]).

The available evidence derived from clinical observations and autopsy series distinguish Covid-19-associated coagulopathy from thrombotic microangiopathy and DIC. Potential overlaps can be observed in critically ill patients in whom circulatory collapse, multi-organ system failure, refractory hypoxemia and ARDS cause full-blown DIC.

Thrombotic microangiopathy

The prototypical features of thrombotic microangiopathy are Coomb’s negative hemolytic anemia, thrombocytopenia and microvascular platelet thrombi. The most common disorders associated with thrombotic microangiopathy are thrombotic thrombocytopenia purpura (TTP) and hemolytic uremia syndrome (HUS). Organ dysfunction involving kidneys, brain and gastrointestinal tract is the result of impaired perfusion. There are primary and secondary causes of TTP and HUS. Secondary causes of TTP include infections (viral, bacterial), pregnancy, collagen-vascular diseases and drugs. Secondary causes of HUS include infections (most commonly enteric pathogens), solid organ and bone marrow transplant recipients, drugs and pregnancy. Thrombotic microangiopathy is a well-described complication of preeclampsia and eclampsia. The typical laboratory features of thrombotic microangiopathy include anemia (with schistocytes, reticulocytosis, plasma free hemoglobin, elevated LDH and decreased haptoglobin), and thrombocytopenia. In TTP, VWF cleaving protease levels are low. The pathological features include disseminated arteriolar and capillary thrombi consisting of aggregated platelets, VWF and fibrin with adjacent vascular endothelial cell swelling. Bleeding is not common in thrombotic microangiopathy.

Disseminated intravascular coagulation

DIC is recognized as a syndrome that complicates a variety of diseases and conditions with systemic activation of coagulation leading to thrombotic obstruction of small and less commonly medium-sized blood vessels. Unlike microangiopathies and Covid-19-associated coagulopathy, bleeding can dominate the clinical phenotype of DIC. In addition to activation of coagulation proteins, tissue factor and vascular endothelial cells, DIC is associated with activation of the fibrinolytic system, reduced endothelial cell surface proteases (antithrombin, protein C) and thrombocytopenia. The most common causes of DIC are severe infection, sepsis, major trauma, malignancy (acute or chronic DIC), complications of pregnancy, toxin exposures, severe allergic reactions and immunologic reactions (e.g. blood product transfusion).

The laboratory features of DIC vary widely depending on the stage encountered. In early DIC, there is compensated activation of the hemostatic system, however with progression to decompensated hemostatic activation, characteristic findings are observed. These include thrombocytopenia, increased PT and PTT, elevated fibrin(ogen) degradation products and decreased protease inhibition. Fibrinogen levels vary, however, in advanced stages of DIC fibrinogen levels decrease. VWF and factor VIII levels are typically increased from endothelial cell activation, but historically they are not elevated to the degree currently being observed in Covid-19-associated coagulopathy (Table 1).

Table 1 Distinguishing laboratory features of disseminated intravascular coagulation, thrombotic microangiopathy and Covid-19- associated coagulopathy
Full size table

Guidelines and consensus statements

The International Society on Thrombosis and Haemostasis published an interim guidance statement for the recognition and management of coagulopathy in Covid-19 [87]. The document highlights several key factors, including an elevated D-dimer and its association with poor clinical outcomes, lack of thrombocytopenia, and late onset DIC in some patients. The recommendation for treatment calls for LMWH administered at prophylaxis doses pending the emergence of additional data.

The British Society of Hematology has recommended use of the ISTH DIC score [88, 89] as a prognostic indicator in patients with Covid-19 to guide treatment. Specifically in the absence of a bleeding phenotype, therapeutic doses of anticoagulants should be considered; however, prophylactic doses of either unfractionated heparin or LMWH are recommended (https://b-s-h.org.uk).

The American Society of Hematology has recommended thromboprophylaxis with either LMWH or fondaparinux (suggested over UFH to reduce patient contact) unless the risk of bleeding exceeds the risk of thrombosis. Dose adjustment for obesity should be considered. In patients with a contraindication for anticoagulation, pneumatic compression devices should be used (April 17, 2020 www.ash.com). Post-discharge thromboprophylaxis in patients with Covid-19 using a regulatory agency approved regimen (betrixaban 160 mg as a first dose, followed by 80 mg daily for 35–42 days or rivaroxaban 10 mg daily for 31–39 days) is favored.

The American College of Cardiology [90] recommended pharmacological VTE prophylaxis in Covid-19 patients requiring ICU-level care as well as those with pneumonia, respiratory failure or other comorbid factors such as heart failure, cancer, prolonged periods of immobility, and possibly pregnant women who are hospitalized. Extended post-discharge prophylaxis was considered reasonable for high risk patients (reduced mobility, co-morbid factors such as active cancer and possibly an elevated D-dimer at the time of discharge).

A consensus statement from several national Chinese societies and working groups [91] highlighted the importance of thromboprophylaxis and vigilant monitoring for thrombotic complications among patients with Covid-19 infection.

The Anticoagulation Forum (ACF) has recently drafted a guidance document for anticoagulation management employing case-based scenarios for patients with Covid-19 requiring hospitalization as well as for patients with indications for anticoagulation who are at risk for infection.

Clinical trials of anticoagulant therapy in patients with Covid-19 infection

At the time of this writing, there were eight clinical trials of anticoagulation in patients with Covid-19 registered on Clinicaltrials.gov. Two of the trials are actively recruiting. A majority of the trials are designed to compare traditional prophylactic VTE doses of LMWH with higher doses or treatment doses. One of the trials is designed to study patients with acute coronary syndrome as a complication of Covid-19 infection and includes aspirin, clopidogrel and rivaroxaban (2.5 mg twice daily). The proposed sample size is 3170 participants.

Anticoagulation and hemostasis agent decisions

The acuity of illness in some patients with Covid-19 pneumonia complicated by end-organ injury (liver, kidneys), coupled by the administration of a wide-variety of medications that may include anti-viral and anti-inflammatory agents should alert clinicians, pharmacists and other health care providers to potential drug-drug interactions and drug-related adverse effects (reviewed in Hermans) [92]. Careful consideration of drug and dose selection and close observation is particularly important for patients that have inherited disorders of hemostasis, hemophilia A, hemophilia B and Von Willebrand disease who require regular replacement therapy. In addition to develo** specific management algorithms for patients with Covid-19, the ever-changing landscape created by the pandemic has and will likely continue to impact the drug and equipment supply chain, access to coagulation monitoring, laboratories and pharmacies. Under these circumstances, anticoagulants that do not require regular laboratory monitoring or the use of point-of-care testing and remote coagulation management are favored. Disorders of hemostasis, under ideal circumstances, would be treated with longer half-life replacement products, including those that can be administered subcutaneously.

Conclusions and future directions

Covid-19 infections are characterized by widely variable phonotypic expressions that involve most major organs and organ systems. An acquired syndrome known as Covid-19-associated coagulopathy has emerged and proven itself to be common, multifactorial with involvement of the venous, arterial and microcirculatory systems and distinct from other viral illnesses. The available information distinguishes Covid-19-associated coagulopathy from DIC and thrombotic microangiopathy in its early stages and while anticoagulant therapy for thromboprophylaxis has been recommended by all major societies in the fields of cardiology, hematology and thrombosis optimal treatment has not yet been established through rigorously conducted clinical trials.

While many unanswered questions remain, the etiology of Covid-19-associated coagulopathy appears to follow Virchow’s Triad (Fig. 5). The inclusion of thrombosis substudies in ongoing clinical trials of anti-viral, anti-inflammatory and immune-modulating therapies is strongly encouraged as are dedicated studies targeting pathobiology-based targets that could include NETs, VWF, platelets and factor XI among others.

Fig. 5
figure 5

Virchow’s Triad represents a fundamental construct in which three components interact to establish an environment favoring or provoking thrombosis. They include abnormalities of the blood vessel wall or endothelial surface, altered blood flow and prothrombotic constituents within the circulating blood. In Covid-19-associated coagulopathy there is wide-scale endothelial cell inflammation and dysfunction, abnormal flow dynamics and activated platelets, high concentrations of von Willebrand Factor, cell free DNA, histones and viral RNA that collectively cause factor XI activation, thrombin generation and fibrin formation

Full size image